News & Events

DMG-ACT meeting in the Alps is supported by SNF

We are very happy to announce that the annual DMG-ACT meeting will this year be held in Zurich, at Campus Balgrist from October 30th to November 2nd 2022. We are looking forward to new insights and discussions.

Tiwari foundation supports another year of research on drug resistance of DMG cells, July 2022

Thanks to the generous donation of the “Tiwari Foundation”, USA we will target several molecules of PI3K pathway in order to identify their role in DMG resistance or sensitivity to ONC201 and potentially develop alternative combination therapies to overcome this resistance for children diagnosed with DMG.

Publication in “Neuro-Oncology” on the effect of imipridones on tumor cells, February 2022

We are pleased to announce that our manuscript on effects of imipridones was recently published in journal Neuro-Oncology.  Neuro-Oncology is a prestigious peer-reviewed medical journal that is well read by the neurooncology community.

The manuscript is the first to establish the efficacy of ONC201, ONC206, and combination in DMG/DIPGs and provide a detail molecular mechanism of drug action.  Data reported in this manuscript have enabled the initiation of two clinical trials (PNOC022, and PNOC023) through Pacific Pediatric Neuro-Oncology Consortium for treatment of children diagnosed with DMG.

We thank our supporters and donors  for supporting this work.

PNOC023 open for enrollment of adult patients, February 2022

We are very excited to announce that we are activated for patient enrollment on this clinical trial as the only European site. The aim of the trial is to evaluate safety and efficacy of ONOC026 in DIPG/DMG patients and patients with a recurrent primary malignant CNS tumor. The study divides into two parts: a dose finding phase and a target validation phase. It is anticipated to enroll 20 patients at the University Children’s Hospital Zurich. Currently only patients at the age of 18 – 21 years can be included in Switzerland.

Generous donation from private sponsor, January 2022

An international private donor supported the DIPG/DMG center Zurich with a generous donation. This funds will be used to pertain high quality pre-clinical investigations and supportive measures to obtain approval for clinical trials in Switzerland.

PNOC026 open for patient enrollment, August 30th 2021

The purpose of this study is to evaluate the efficacy and safety of DAY101 in pediatric patients aged 6 months to 25 years of age as monotherapy in pediatric patients with a recurrent or progressive LGG harboring a known activating BRAF alteration. The primary endpoint is ORR as defined by the RANO criteria, determined by an IRC.

Retreat Meeting of DIPG/DMG Center in Zurich July 6th 2021

Pre-clinical as well as clinical researchers and tem members joined in July 2021 for a retreat meeting at Campus Balgrist, Zurich. Current and upcoming trials and research projects as well as planned grants were presented and discussed. An update was also given on the FUS project by Dr. Beat Werner. It was very valuable to share the development so far and the achieved goals with the whole team. Especially after such a long period of distance keeping and video conferencing due to pandemic related restrictions.

Yuvaan Tiwari Postdoctoral Fellowship at University Children’s Hospital Zurich, starting July 1st

We are very honored and grateful for the generous donation we received from Satya and Parvati Tiwari to establish the “Yuvaan Tiwari Postdoctoral Fellowship” at the DIPG/DMG Research Center, led by Prof. Dr. Javad Nazarian. Dr. Evan Santos will start this position on July 1, 2021. This donation will enable to further advance research on these deadly tumors.

PNOC019 open for patient enrollment, April 14th 2021

This international, multi-center clinical trial is open for patients (6 months – 22 years) with recurrent or progressive High Grade Glioma (HGG). The study aims to evaluate the immunological local and systemic changes following neoadjuvant checkpoint inhibition, as well as the preliminary efficacy of neoadjuvant checkpoint inhibition followed by surgery and adjuvant combination checkpoint inhibition in children and young adults with progressive or recurrent HGG.

PNOC007 open for patient enrollment, December 17th 2020

The purpose of this study is to test the safety and first signs of efficacy of a H3.3K27M specific peptide vaccine (K27M/TT), in combination with a drug called poly-ICLC and Nivolumab in children and young adults (3-21 years) that have been newly diagnosed with a diffuse intrinsic pontine glioma (DIPG) or another type of glioma.  Thus is a multi-center clinical trial with multiple sites in the USA and one at the University Children’s Hospital Zurich in Switzerland.

SNF Sinergia Grant at DMG Center Zurich, November 26th 2020

The Swiss  National Fund approved the Sinergia proposal of Dr. Javad Nazarian as the lead PI and Prof.Dr. Mehmet Fatih Yanik (ETH) and Dr.Sebastian Waszak (Centre for Molecular Medicine Norway) as co-applicants. With 3.1 Mio CHF over 4 years the team aims to merge novel technologies for rapid identification and validation of therapies capable of extending the survival of children diagnosed with diffuse midline gliomas. The proposal includes a stepwise process that employs expertise of a multidisciplinary team to achieve a significant impact on patient treatment options.

We are very much looking forward to first results from this interdisciplinary research team!

Trans-Atlantic DIPG/DMG Tumor board, November 9th 2020

The first Trans-Atlantic Tumor Board took place on November 9th, 2020 from 5 PM – 6 PM CET / 8 AM- 9 AM PT. More than 20 experts in the care of children and young adults with Diffuse Midline Glioma  from UCSF and Zurich Children’s Hospital  were present. The combined discussion with experts around the world truly enhances the evaluation and recommendations for these patients. The combined tumor board will take place on a weekly basis.

contact
Source: Universitätsklinik Balgrist, Bilddokumentation